Clinical Update (11/2007)
Brief summaries of recent clinical developments in the device industry, including a new electronic wound monitor, a tiny radio with medical potential, cutting-edge diabetes research, and advanced imaging for cancer detection and treatment.
You may also be interested in...
Cizzle Biotechnology is focusing on the gene Ciz1 and its variant, found in small-cell lung cancer. The trigger for the start-up's formation was the finding that cells require Ciz1 to grow, and that variant forms could be used for selective targeting of cancer cells, especially small-cell lung cancer. The company's founders have shown that blocking the disrupted form of Ciz1, using a small interfering RNA (siRNA) targeted to the variant, prevented cell proliferation and growth in vitro. The specificity of the Ciz1 variant also gives it potential as a biomarker for early detection of lung cancer.
The president’s executive order aims to give smaller companies a leg up over foreign competitors, among other objectives.
No device-related warning letters were released by the US FDA the week of 26 January.